相关实验视频
Updated: Sep 8, 2025
08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
40.5K
在喘和过敏性支气管肺性阿斯伯吉洛症中,血清曼诺斯结合性莱克水平
Inderpaul Singh Sehgal1, Hansraj Choudhary2, Valliappan Muthu1
1Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India.
Mycopathologia
|July 31, 2025
概括
曼诺结合性莱克 (MBL) 对于先天免疫非常重要. 虽然喘组的MBL水平在患病率上没有差异,但在过敏支气管肺炎 (ABPA) 患者中观察到较低的MBL平均水平.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 传染性疾病 传染性疾病
背景情况:
- 曼诺结合性莱克 (MBL) 在对Aspergillus fumigatus. 菌的天生的免疫力中起作用.
- 喘患者的MBL水平可能有所不同,这可能会影响对像ABPA这样的真菌感染的易感性.
研究的目的:
- 调查MBL水平与喘严重程度之间的关联,特别是在患有和没有过敏支气管肺性阿斯伯吉洛症 (ABPA) 的患者中.
- 确定降低的MBL水平是否与ABPA患者的临床特征,免疫标记或肺功能相关.
主要方法:
- 一项涉及154名成年参与者的前性横截面研究:喘,阿斯伯菌敏感性喘 (ASA) 和ABPA组.
- 血清MBL水平使用酶相关免疫吸收试验 (ELISA) 量化.
- 通过使用三个不同的值 (例如,<200 ng/mL) 定义了降低的MBL水平.
主要成果:
- 在喘,ASA和ABPA组中,没有发现降低MBL水平的流行率有显著差异.
- 与喘 (1159 ng/mL) 和ASA (1593 ng/mL) 组相比,ABPA患者 (961 ng/mL) 的平均MBL水平显着较低 (p=0.048).
- 在ABPA患者中,降低的MBL水平 (≤359 ng/mL) 与临床特征,免疫学标志物,肺功能或放射学发现没有相关性.
结论:
- 虽然ABPA患者的MBL水平较低,但MBL患病率降低并不是喘表型之间的区分因素.
- 在ABPA患者的低MBL水平似乎不会影响疾病的严重程度或临床表现.
相关概念视频
01:20Asthma: Pathogenesis and Management
573
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
573
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
446
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
446
01:26Asthma-II: Pathophysiology and Classification
2.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K